Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovAliX and Galapagos have signed drug discovery collaboration in the field of osteoarthritis.
Subscribe to our email newsletter
NovAliX will discover specific small molecule lead candidates for a novel, validated osteoarthritis target chosen by Galapagos, under the collaboration.
The company will identify hits using its Graffinity fragment-based screening technology that combines chemical micro-arrays with a proprietary SPR-imaging method for the detection of compound-protein interactions.
The company will then further progress the program to the lead candidate stage by applying its medicinal chemistry and structural biology expertise.
NovAliX will receive technology access fees, research funding and is eligible to receive success-based milestones from Galapagos.
Galapagos Drug Discovery senior vice president Graham Dixon said they look forward to using NovAliX’s capabilities in biophysics and lead generation methodologies for this novel target based drug discovery program.